Donate

industry_news_banner

On April 11, Catalyst Biosciences, a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, reached a key milestone towards starting human trials with completion of the CB 2679d/ISU304 toxicology studies. Their press release can be read in full here.

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.